Metronidazole (MetroGel, Rozex)
Metronidazole (MetroGel, Rozex) is prescription-only
We review what you can buy over the counter, so nothing carrying it appears here. This page is the reference — what it does, what the evidence supports, and what to raise with a prescriber.
The full metronidazole (metrogel, rozex) guide
For most of the last thirty years, a rosacea prescription in the United States meant this molecule.
Metronidazole earned that position by working reliably and being cheap, not by anyone understanding it — it is an antibiotic that almost certainly does not treat rosacea by killing bacteria, and its own FDA label declines to explain the mechanism. The best current explanation involves neutrophils and free radicals rather than infection at all.
Where the evidence stands, by concern
Evidence for an ingredient is not one grade — it differs concern by concern. Each row below was researched separately against regulatory approvals, clinical guidelines, and trials our team opened and verified; the band and dots rank how central metronidazole (metrogel, rozex) is to treating that concern, from first-line therapy down to supportive care, at treatment-level doses and vehicles. A product's own grade weighs its actual formula.
How it's regulated in the US
FDA does not classify ingredients — it classifies products, by what they are sold to do. The same molecule can be a drug active in one product and a cosmetic ingredient in the next, and only the claim on the label decides which. What follows is a statement about that legal standing, not about whether it works — the evidence question is answered separately above.
Approved drug Topical metronidazole has been the prescription workhorse for rosacea since the late 1980s. There is no cosmetic version of it and no OTC route to it.
- rosacea FDA-approved 0.75 percent and 1 percent gel, cream and lotion
Approved by FDA under a New Drug Application
Permitted label wording “For the topical treatment of inflammatory lesions and erythema of rosacea”
Topical metronidazole holds FDA approval for the inflammatory lesions of rosacea in 0.75% and 1% gels, creams and lotions, and it has been evaluated in vehicle-controlled trials since the late 1980s. The 2019 British Journal of Dermatology systematic review of rosacea interventions, which applied GRADE ratings by phenotype, confirms a real effect on papulopustular disease. Its ceiling is now well characterised: in the ATTRACT head-to-head trial, twice-daily metronidazole 0.75% reduced inflammatory lesions by 73.7% at week 16 against 83% for once-daily ivermectin, with 75.4% versus 84.9% reaching clear or almost clear. That is a genuinely effective drug that has since been outperformed — which is a different verdict from a drug that does not work.
How it works
Metronidazole's day job elsewhere in medicine is killing anaerobic bacteria and protozoa: inside an oxygen-poor cell its nitro group gets reduced into reactive intermediates that shred microbial DNA. That chemistry is real, but the organisms it targets are not the ones implicated in rosacea, and no convincing antimicrobial explanation for the clinical benefit has emerged. The label reflects this — it states the mechanism in rosacea is unknown. The more persuasive account is antioxidant and immunomodulatory. Rosacea involves an overactive innate immune response in which neutrophils accumulate around follicles and release reactive oxygen species that damage the surrounding tissue and perpetuate inflammation. Work dating back to a 1986 British Journal of Dermatology paper found metronidazole suppressing neutrophil-generated oxidative activity, and subsequent studies described both a reduction in how much reactive oxygen species neutrophils produce and direct scavenging of the radicals themselves. On that reading the drug is not fighting an infection; it is turning down an oxidative amplifier. A useful consequence of this being an anti-inflammatory rather than an antibacterial effect: long-term use of topical metronidazole for rosacea has not been associated with the resistance concerns that limit prolonged topical antibiotic use in acne.
Key benefits
- Reduces inflammatory rosacea papules and pustules over eight to twelve weeks
- Decades of clinical use with a well-mapped safety profile
- Inexpensive and widely available as a generic in several vehicles
- Gel, cream and lotion bases suit oily through to very dry skin
- Suppresses neutrophil oxidative activity rather than acting as an antibiotic
- Suitable for long-term maintenance without antimicrobial resistance concerns
Concentration & usage
Two strengths are approved and the difference between them is frequency rather than potency: 0.75% is generally applied twice daily, 1% once daily, and comparative work has not established a meaningful efficacy gap. Vehicle choice matters more than the number for most people — gel suits oily and combination skin, cream and lotion suit the dry, easily stung skin that often accompanies rosacea. Apply a thin film to the whole affected area after cleansing rather than dabbing individual bumps, and let it settle before makeup. It is prescription-only in the United States; nothing sold as a cosmetic contains it. Give it eight to twelve weeks before judging, and expect to continue in some form, since lesions return after stopping.
Who it's for & who should be cautious
Who it's for
It remains a sound first-line choice for mild-to-moderate papulopustular rosacea, and its cost is a legitimate clinical argument rather than a compromise — a treatment someone can actually afford to use for years beats a better one they abandon after two months. The lotion and cream vehicles make it a good fit for people whose rosacea skin cannot tolerate much, and it sits comfortably alongside gentle cleansers, ceramide moisturisers and daily mineral sunscreen.
Who should be cautious
It does very little for the redness-and-flushing subtype, so anyone whose main complaint is a persistent flush with visible vessels and few bumps should not expect much. Local dryness, scaling and itching were common in trials, affecting roughly a sixth to a quarter of users, which on already-fragile skin can be enough to derail the routine without a good moisturiser alongside. The label advises care in anyone with a history of blood dyscrasia and notes peripheral neuropathy reports with metronidazole, mostly systemic. High-dose oral metronidazole showed carcinogenic activity in rodents; the relevance to a thin facial film is unclear but is why the label mentions it. Breastfeeding is not recommended on the label, and pregnancy use is a conversation to have rather than assume.
Pairs with & conflicts
Pairs well with: Azelaic Acid, Niacinamide (Vitamin B3), Ceramides, Colloidal Oatmeal, Zinc Oxide
Myths & facts
Myth: Metronidazole treats rosacea by killing the bacteria causing it.
Reality: Rosacea is not a bacterial infection, and the anaerobes metronidazole kills elsewhere in the body are not present in the relevant skin. The prescribing information states the rosacea mechanism is unknown, and the leading explanation is suppression of neutrophil-derived reactive oxygen species. The antibiotic label is a fact about the molecule's other uses, not an account of what it does on a face.
Myth: You can't drink alcohol while using metronidazole gel.
Reality: The disulfiram-like reaction people have heard about comes from oral metronidazole and even there the evidence is weaker than the folklore. Systemic absorption from a thin film of topical gel is minimal, and the topical labels do not carry an alcohol warning. Alcohol is worth moderating for rosacea because it triggers flushing — a completely separate reason.
Myth: Since ivermectin beat it in a head-to-head trial, metronidazole is obsolete.
Reality: It lost on margin, not on effect: 73.7% lesion reduction is a substantial result, and three quarters of participants reached clear or almost clear. Cost, availability and the choice of gel, cream or lotion vehicles keep it clinically useful, and for many people it controls the condition perfectly well. 'Second-best in one trial' is not the same as ineffective.
Frequently asked questions
How long does topical metronidazole take to work on rosacea?
Meaningful change generally takes eight to twelve weeks, with gradual improvement in bumps and pustules rather than a sudden clearing. Judging it at three or four weeks is the most common reason people conclude it failed. If twelve consistent weeks have produced nothing, that is the point to discuss alternatives.
Is 1% metronidazole stronger than 0.75%?
Not in any way that has been shown to matter clinically. The practical difference is dosing convenience — 1% is generally once daily, 0.75% twice — and comparative studies have not demonstrated a clear efficacy advantage for either. Vehicle and how consistently you use it will affect your result far more than the percentage.
Will metronidazole help the redness on my cheeks?
Its demonstrated benefit is on inflammatory papules and pustules; the persistent background redness and visible vessels of rosacea run on vascular mechanisms it barely touches. Some redness does fade as the inflammatory lesions settle, but if flushing is your main complaint you will likely need something aimed at blood vessels instead.
Can metronidazole be used with makeup or sunscreen?
Yes — apply it to clean skin, give it a minute or two to absorb, then layer sunscreen and makeup over the top. Daily sun protection is not optional alongside it, since ultraviolet exposure is among the most consistent rosacea triggers and will undercut the treatment's progress.
Do I have to keep using it forever?
Rosacea is controlled rather than cured, and lesions typically return within months of stopping. Most people move to a maintenance schedule — continuing daily or dropping to a reduced frequency once the skin is settled — rather than stopping outright. Long-term use is well tolerated and does not carry the resistance concerns that limit prolonged topical antibiotics in acne.